| Year |
Citation |
Score |
| 2014 |
Lin Y, Murray MA, Garrett IR, Gutierrez GE, Nyman JS, Mundy G, Fast D, Gellenbeck KW, Chandra A, Ramakrishnan S. A targeted approach for evaluating preclinical activity of botanical extracts for support of bone health. Journal of Nutritional Science. 3: e13. PMID 25191605 DOI: 10.1017/Jns.2014.5 |
0.49 |
|
| 2013 |
Yang W, Guo D, Harris MA, Cui Y, Gluhak-Heinrich J, Wu J, Chen XD, Skinner C, Nyman JS, Edwards JR, Mundy GR, Lichtler A, Kream BE, Rowe DW, Kalajzic I, et al. Bmp2 in osteoblasts of periosteum and trabecular bone links bone formation to vascularization and mesenchymal stem cells. Journal of Cell Science. 126: 4085-98. PMID 23843612 DOI: 10.1242/Jcs.118596 |
0.439 |
|
| 2013 |
Edwards JR, Perrien DS, Fleming N, Nyman JS, Ono K, Connelly L, Moore MM, Lwin ST, Yull FE, Mundy GR, Elefteriou F. Silent information regulator (Sir)T1 inhibits NF-κB signaling to maintain normal skeletal remodeling. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 28: 960-9. PMID 23172686 DOI: 10.1002/Jbmr.1824 |
0.402 |
|
| 2012 |
Zhuang J, Zhang J, Lwin ST, Edwards JR, Edwards CM, Mundy GR, Yang X. Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells. Plos One. 7: e48871. PMID 23173040 DOI: 10.1371/Journal.Pone.0048871 |
0.394 |
|
| 2012 |
Hiraga T, Myoui A, Hashimoto N, Sasaki A, Hata K, Morita Y, Yoshikawa H, Rosen CJ, Mundy GR, Yoneda T. Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Research. 72: 4238-49. PMID 22738911 DOI: 10.1158/0008-5472.CAN-11-3061 |
0.459 |
|
| 2012 |
Fowler JA, Mundy GR, Lwin ST, Edwards CM. Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Research. 72: 2183-9. PMID 22374979 DOI: 10.1158/0008-5472.CAN-11-2067 |
0.476 |
|
| 2011 |
Biswas S, Nyman JS, Alvarez J, Chakrabarti A, Ayres A, Sterling J, Edwards J, Rana T, Johnson R, Perrien DS, Lonning S, Shyr Y, Matrisian LM, Mundy GR. Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. Plos One. 6: e27090. PMID 22096521 DOI: 10.1371/Journal.Pone.0027090 |
0.428 |
|
| 2011 |
Fowler JA, Lwin ST, Drake MT, Edwards JR, Kyle RA, Mundy GR, Edwards CM. Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood. 118: 5872-82. PMID 21908434 DOI: 10.1182/Blood-2011-01-330407 |
0.352 |
|
| 2011 |
Johnson RW, Merkel AR, Danilin S, Nguyen MP, Mundy GR, Sterling JA. 6-Thioguanine inhibition of parathyroid hormone-related protein expression is mediated by GLI2. Anticancer Research. 31: 2705-12. PMID 21868511 |
0.43 |
|
| 2011 |
Nyman JS, Lynch CC, Perrien DS, Thiolloy S, O'Quinn EC, Patil CA, Bi X, Pharr GM, Mahadevan-Jansen A, Mundy GR. Differential effects between the loss of MMP-2 and MMP-9 on structural and tissue-level properties of bone. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 26: 1252-60. PMID 21611966 DOI: 10.1002/Jbmr.326 |
0.337 |
|
| 2011 |
Edwards JR, Mundy GR. Advances in osteoclast biology: old findings and new insights from mouse models. Nature Reviews. Rheumatology. 7: 235-43. PMID 21386794 DOI: 10.1038/nrrheum.2011.23 |
0.379 |
|
| 2011 |
Johnson RW, Nguyen MP, Padalecki SS, Grubbs BG, Merkel AR, Oyajobi BO, Matrisian LM, Mundy GR, Sterling JA. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Research. 71: 822-31. PMID 21189326 DOI: 10.1158/0008-5472.Can-10-2993 |
0.434 |
|
| 2011 |
Johnson LC, Johnson RW, Munoz SA, Mundy GR, Peterson TE, Sterling JA. Longitudinal live animal micro-CT allows for quantitative analysis of tumor-induced bone destruction. Bone. 48: 141-51. PMID 20685406 DOI: 10.1016/j.bone.2010.05.033 |
0.421 |
|
| 2011 |
Sterling JA, Edwards JR, Martin TJ, Mundy GR. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone. 48: 6-15. PMID 20643235 DOI: 10.1016/j.bone.2010.07.015 |
0.497 |
|
| 2011 |
Thiolloy S, Edwards J, Fingleton B, Rifkin D, Schwartz HS, Mundy G, Matrisian LM, Lynch CC. Abstract 3112: Host MMP-2 impacts tumor survival in the metastatic bone microenvironment through a TGFβ dependent mechanism Cancer Research. 71: 3112-3112. DOI: 10.1158/1538-7445.Am2011-3112 |
0.532 |
|
| 2010 |
Ruppender NS, Merkel AR, Martin TJ, Mundy GR, Sterling JA, Guelcher SA. Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells. Plos One. 5: e15451. PMID 21085597 DOI: 10.1371/Journal.Pone.0015451 |
0.482 |
|
| 2010 |
Edwards JR, Nyman JS, Lwin ST, Moore MM, Esparza J, O'Quinn EC, Hart AJ, Biswas S, Patil CA, Lonning S, Mahadevan-Jansen A, Mundy GR. Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 25: 2419-26. PMID 20499365 DOI: 10.1002/Jbmr.139 |
0.399 |
|
| 2010 |
Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ. Metastasis and bone loss: advancing treatment and prevention. Cancer Treatment Reviews. 36: 615-20. PMID 20478658 DOI: 10.1016/J.Ctrv.2010.04.003 |
0.425 |
|
| 2010 |
Yoshii T, Hafeman AE, Nyman JS, Esparza JM, Shinomiya K, Spengler DM, Mundy GR, Gutierrez GE, Guelcher SA. A sustained release of lovastatin from biodegradable, elastomeric polyurethane scaffolds for enhanced bone regeneration. Tissue Engineering. Part A. 16: 2369-79. PMID 20205517 DOI: 10.1089/Ten.Tea.2009.0585 |
0.379 |
|
| 2010 |
Wang W, Nyman JS, Moss HE, Gutierrez G, Mundy GR, Yang X, Elefteriou F. Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 25: 1658-67. PMID 20200958 DOI: 10.1002/Jbmr.42 |
0.315 |
|
| 2010 |
Pivonka P, Zimak J, Smith DW, Gardiner BS, Dunstan CR, Sims NA, Martin TJ, Mundy GR. Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling. Journal of Theoretical Biology. 262: 306-16. PMID 19782692 DOI: 10.1016/j.jtbi.2009.09.021 |
0.444 |
|
| 2010 |
Edwards JR, Fowler J, Ruppender N, Sterling J, Lwin S, Johnson J, Edwards C, Mundy G. Breast cancer, melanoma and myeloma cells induce generalized bone loss Bone. 47. DOI: 10.1016/J.Bone.2010.04.125 |
0.448 |
|
| 2010 |
Edwards⁎ J, Nyman J, Moore M, Biswas S, Mahadevan-Jansen A, Mundy G. TGF-beta blockade by 1D11 antibody treatment improves bone volume, strength and micro-structural properties in vivo Bone. 47: S64. DOI: 10.1016/J.Bone.2010.04.123 |
0.346 |
|
| 2010 |
Edwards JR, Connelly L, Moore M, Lwin S, Yull F, Nyman J, Elefteriou F, Mundy G. NFKB activity is elevated in aging bone, uncouples osteoblasts and osteoclasts in vivo and mediates SIRT1 regulation of bone cells Bone. 47. DOI: 10.1016/J.Bone.2010.04.067 |
0.511 |
|
| 2009 |
Fowler JA, Mundy GR, Lwin ST, Lynch CC, Edwards CM. A murine model of myeloma that allows genetic manipulation of the host microenvironment. Disease Models & Mechanisms. 2: 604-11. PMID 19779066 DOI: 10.1242/dmm.003160 |
0.337 |
|
| 2009 |
Lipton A, Brown GA, Mundy GR, Roodman GD, Smith MR. New opportunities for the management of cancer-related bone complications. Clinical Advances in Hematology & Oncology : H&O. 7: 1-30; quiz 31. PMID 19741583 |
0.321 |
|
| 2009 |
Thiolloy S, Halpern J, Holt GE, Schwartz HS, Mundy GR, Matrisian LM, Lynch CC. Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis. Cancer Research. 69: 6747-55. PMID 19679556 DOI: 10.1158/0008-5472.Can-08-3949 |
0.306 |
|
| 2009 |
Edwards CM, Lwin ST, Fowler JA, Oyajobi BO, Zhuang J, Bates AL, Mundy GR. Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo. American Journal of Hematology. 84: 268-72. PMID 19296472 DOI: 10.1002/ajh.21374 |
0.446 |
|
| 2009 |
Zhao M, Ko SY, Liu JH, Chen D, Zhang J, Wang B, Harris SE, Oyajobi BO, Mundy GR. Inhibition of microtubule assembly in osteoblasts stimulates bone morphogenetic protein 2 expression and bone formation through transcription factor Gli2. Molecular and Cellular Biology. 29: 1291-305. PMID 19103752 DOI: 10.1128/Mcb.01566-08 |
0.41 |
|
| 2009 |
Izbicka E, Niewolna M, Yoneda T, Lowe C, Boyce B, Mundy G. pp60 c-src expression and activity in MG-63 osteoblastic cells modulated by PTH but not required for PTH-mediated adenylate cyclase response. Journal of Bone and Mineral Research. 9: 127-132. PMID 7512305 DOI: 10.1002/Jbmr.5650090117 |
0.312 |
|
| 2008 |
Edwards CM, Mundy GR. Eph receptors and ephrin signaling pathways: a role in bone homeostasis. International Journal of Medical Sciences. 5: 263-72. PMID 18797510 |
0.444 |
|
| 2008 |
Pivonka P, Zimak J, Smith DW, Gardiner BS, Dunstan CR, Sims NA, Martin TJ, Mundy GR. Model structure and control of bone remodeling: a theoretical study. Bone. 43: 249-63. PMID 18514606 DOI: 10.1016/j.bone.2008.03.025 |
0.415 |
|
| 2008 |
Edwards CM, Zhuang J, Mundy GR. The pathogenesis of the bone disease of multiple myeloma. Bone. 42: 1007-13. PMID 18406675 DOI: 10.1016/j.bone.2008.01.027 |
0.463 |
|
| 2008 |
Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, McCluskey B, Munoz S, Grubbs B, Mundy GR. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood. 111: 2833-42. PMID 18094333 DOI: 10.1182/blood-2007-03-077685 |
0.462 |
|
| 2008 |
Edwards J, Dumitrescu L, Sterling J, Bates A, Mundy G. P34. Melanoma-induced osteolysis is directly mediated through osteoclast formation and activity Cancer Treatment Reviews. 34: 25. DOI: 10.1016/J.Ctrv.2008.03.076 |
0.303 |
|
| 2008 |
Bates A, Mundy G, Edwards C. P21. Myeloma cells decrease EphB4 expression in osteoblasts: A novel mechanism for regulation of bone formation in multiple myeloma Cancer Treatment Reviews. 34: 20. DOI: 10.1016/J.Ctrv.2008.03.063 |
0.492 |
|
| 2007 |
Mundy GR. Osteoporosis and inflammation. Nutrition Reviews. 65: S147-51. PMID 18240539 |
0.415 |
|
| 2007 |
Mundy G, Gutierrez G, Garrett R, Gallwitz W, Rossini G, Christiansen C, Langenberg A. Proteasome inhibitors stimulate both bone formation and hair growth by similar mechanisms. Annals of the New York Academy of Sciences. 1117: 298-301. PMID 18056049 DOI: 10.1196/Annals.1402.077 |
0.445 |
|
| 2007 |
Oyajobi BO, Garrett IR, Gupta A, Flores A, Esparza J, Muñoz S, Zhao M, Mundy GR. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. British Journal of Haematology. 139: 434-8. PMID 17910634 DOI: 10.1111/j.1365-2141.2007.06829.x |
0.463 |
|
| 2007 |
Mundy GR, Edwards JR. The osteoclast-not always guilty. Cell Metabolism. 6: 157-9. PMID 17767902 DOI: 10.1016/j.cmet.2007.08.008 |
0.322 |
|
| 2007 |
Martin TJ, Mundy GR. Bone metastasis: can osteoclasts be excluded? Nature. 445: E19; discussion E19-. PMID 17314931 DOI: 10.1038/nature05657 |
0.454 |
|
| 2006 |
Mundy GR, Elefteriou F. Boning up on ephrin signaling. Cell. 126: 441-3. PMID 16901775 DOI: 10.1016/J.Cell.2006.07.015 |
0.418 |
|
| 2006 |
Mundy GR. Nutritional modulators of bone remodeling during aging. The American Journal of Clinical Nutrition. 83: 427S-430S. PMID 16470007 |
0.44 |
|
| 2005 |
Shipman CM, Oyajobi BO, Mundy GR. Advances in the management of myeloma bone disease. Expert Opinion On Pharmacotherapy. 6: 2781-91. PMID 16318429 DOI: 10.1517/14656566.6.16.2781 |
0.426 |
|
| 2005 |
Mundy GR. How can bone turnover markers be best utilized for prediction of skeletal events in patients with solid tumors? Nature Clinical Practice. Oncology. 2: 242-3. PMID 16264958 DOI: 10.1038/ncponc0167 |
0.339 |
|
| 2004 |
Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors (Chur, Switzerland). 22: 233-41. PMID 15621726 DOI: 10.1080/08977190412331279890 |
0.391 |
|
| 2004 |
Mundy GR. The evolving role of bisphosphonates: cancer treatment-induced bone loss. Oncology (Williston Park, N.Y.). 18: 9-10. PMID 15202581 |
0.38 |
|
| 2004 |
Mori Y, Shimizu N, Dallas M, Niewolna M, Story B, Williams PJ, Mundy GR, Yoneda T. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood. 104: 2149-54. PMID 15138161 DOI: 10.1182/blood-2004-01-0236 |
0.328 |
|
| 2004 |
Zhao M, Qiao M, Harris SE, Oyajobi BO, Mundy GR, Chen D. Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo. The Journal of Biological Chemistry. 279: 12854-9. PMID 14701828 DOI: 10.1074/Jbc.M313294200 |
0.406 |
|
| 2003 |
Myoui A, Nishimura R, Williams PJ, Hiraga T, Tamura D, Michigami T, Mundy GR, Yoneda T. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Research. 63: 5028-33. PMID 12941830 |
0.437 |
|
| 2003 |
Zhao M, Qiao M, Oyajobi BO, Mundy GR, Chen D. E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation. The Journal of Biological Chemistry. 278: 27939-44. PMID 12738770 DOI: 10.1074/jbc.M304132200 |
0.362 |
|
| 2003 |
Käkönen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer. 97: 834-9. PMID 12548583 DOI: 10.1002/cncr.11132 |
0.475 |
|
| 2002 |
Gallwitz WE, Guise TA, Mundy GR. Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. The Journal of Clinical Investigation. 110: 1559-72. PMID 12438453 DOI: 10.1172/JCI11936 |
0.318 |
|
| 2002 |
Michigami T, Hiraga T, Williams PJ, Niewolna M, Nishimura R, Mundy GR, Yoneda T. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Research and Treatment. 75: 249-58. PMID 12353814 |
0.371 |
|
| 2002 |
Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Reviews. Cancer. 2: 584-93. PMID 12154351 DOI: 10.1038/nrc867 |
0.388 |
|
| 2002 |
Zhao M, Harris SE, Horn D, Geng Z, Nishimura R, Mundy GR, Chen D. Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation. The Journal of Cell Biology. 157: 1049-60. PMID 12058020 DOI: 10.1083/Jcb.200109012 |
0.422 |
|
| 2002 |
Mundy GR. Directions of drug discovery in osteoporosis. Annual Review of Medicine. 53: 337-54. PMID 11818478 DOI: 10.1146/annurev.med.53.082901.104047 |
0.361 |
|
| 2001 |
Mundy G. Preclinical models of bone metastases. Seminars in Oncology. 28: 2-8. PMID 11544569 DOI: 10.1016/S0093-7754(01)90225-8 |
0.371 |
|
| 2001 |
Mundy G, Gallwitz W. Breast cancer metastasis to bone: pathophysiology and new therapeutic approaches Bone. 29: 296-297. DOI: 10.1016/S8756-3282(01)00516-6 |
0.421 |
|
| 1999 |
Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science (New York, N.Y.). 286: 1946-9. PMID 10583956 DOI: 10.1126/Science.286.5446.1946 |
0.511 |
|
| 1998 |
Body J, Bartl R, Burckhardt P, Delmas PD, Diel I, Fleisch H, Kanis JA, Kyle RA, Mundy G, Paterson AHG, Rubens R. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. Journal of Clinical Oncology. 16: 3890-3899. PMID 9850035 DOI: 10.1200/Jco.1998.16.12.3890 |
0.472 |
|
| 1996 |
Alsina M, Boyce B, Devlin R, Anderson J, Craig F, Mundy G, Roodman G. Development of an in vivo model of human multiple myeloma bone disease Blood. 87: 1495-1501. DOI: 10.1182/Blood.V87.4.1495.Bloodjournal8741495 |
0.503 |
|
| 1994 |
Mundy G, Harris S. 2. Role of TGFβ superfamily in osteoblast differentiation Bone. 15: 225. DOI: 10.1016/8756-3282(94)90713-7 |
0.305 |
|
| 1989 |
Graves DT, Valentin-Opran A, Delgado R, Valente AJ, Mundy G, Piche J. The potential role of platelet-derived growth factor as an autocrine or paracrine factor for human bone cells. Connective Tissue Research. 23: 209-218. PMID 2630171 DOI: 10.3109/03008208909002419 |
0.449 |
|
| 1989 |
Boyce B, Aufdemorte T, Garrett I, Yates A, Mundy G. 10. Local and systemic effects of IL-1 and TNFα on bone resorption Bone. 10: 474. DOI: 10.1016/8756-3282(89)90090-2 |
0.385 |
|
| 1983 |
Ibbotson K, D'Souza S, Ng K, Osborne C, Niall M, Martin T, Mundy G. Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy Science. 221: 1292-1294. PMID 6577602 DOI: 10.1126/Science.6577602 |
0.386 |
|
| Show low-probability matches. |